Oncolytics Biotech Inc.

Today we #WearItPink to bring awareness to #BreastCancer during #BreastCancerAwarenessMonth. #WearItPinkDay #BreastCancerAwareness

Today we shared updates from the #ClinicalTrials of our #immunotherapy candidate for the treatment of #MetastaticBreastCancer and #PancreaticCancer. We look forward to advancing these studies and potentially bringing new treatments to patients in need. Read more in our press release: https://lnkd.in/gutd_bQm #CancerResearch #BreastCancer #PancreaticCancerResearch #biotech #oncology #pelareorep #pela

Our Chief Medical Officer, Thomas Heineman, joined Hüseyin Kandemir of Health and Pharma on an episode of ONCOLife. Watch as he discusses the future of oncolytic viruses and our #ClinicalTrial in #MetastaticBreastCancer: https://lnkd.in/g_9Swntu #BreastCancer #biotech #CancerResearch #oncology #BreastCancerResearch

#Oncolytic #viruses are emerging as a promising development in #cancertreatment, not only destroying #cancer cells but also modulating the #tumor microenvironment to enhance immune responses. I’m thrilled to announce today’s interview with Dr. Thomas Heineman, Chief Medical Officer at Oncolytics Biotech Inc., where we discuss the groundbreaking potential of the novel #oncolyticvirus therapy, #pelareorep, in HR+/HER2- metastatic #breastcancer, along with the latest data from the #BRACELET-1 study.

At Oncolytics, we are driven by the opportunity to improve the lives of people with #cancer. Results from the BRACELET-1 trial showed improved survival in patients with HR+/HER2- metastatic #BreastCancer, and we now have an updated webpage dedicated to it. Check out the new page to learn more: https://lnkd.in/gP2XN_Tb #BreastCancerResearch #biotech #oncology #CancerResearch

CFO Kirk Look and CMO Thomas Heineman had a great fireside chat with Carvey Leung and Louise Chen at the #CantorHCC earlier today. Among the topics covered were the impressive #pelareorep BRACELET-1 #BreastCancer data, #PancreaticCancer, and the work we're doing with Global Coalition for Adaptive Research and Pancreatic Cancer Action Network. You can watch a replay here: https://lnkd.in/eTq2mqV8 #BreastCancerResearch #PancreaticCancerResearch #NY #biotech #NYC #conference #immunotherapy #oncology #OS #PFS

Today, we announced positive results from BRACELET-1, our randomized Phase 2 study evaluating #pelareorep in patients with HR+/HER2- metastatic #BreastCancer. These include an estimated 14-month OS benefit and 5.7-month PFS benefit for patients receiving pelareorep + paclitaxel compared to paclitaxel alone. More details in the PR: https://lnkd.in/gJ7FpkeK #BreastCancerResearch #CancerResearch #OS #PFS #biotech #oncology

In the AWARE-1 and BRACELET-1 clinical trials, our leading #ImmunoTherapy candidate, #pelareorep, shows the potential for our therapy in development to improve treatment outcomes for HR+/HER2- #BreastCancer patients. Learn more: https://lnkd.in/gP2XN_Tb #biotech #BreastCancerResearch #CancerResearch #oncology #immunotherapeutic

Our IND-213 study showed that combining #pelareorep with #paclitaxel nearly doubled overall survival in HR+/HER2- metastatic #BreastCancer patients. This promising data has the potential to accelerate access to patients in need. Learn more: https://lnkd.in/g84Sunm7 #BreastCancerResearch #biotech #immunotherapy #CancerResearch #oncology #pela

Accelerated approval has the power to bring important therapies to patients in need. An example of this was seen with Pfizer’s IBRANCE. Learn more here about accelerated approval and how it provides patients earlier access to safe and effective therapies: https://lnkd.in/gE4qhzag  #BreastCancer #BreastCancerResearch #biotech #oncology #pelareorep #immunotherapy #AcceleratedApproval